Description: Clarient combines diagnostic technologies with pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies. Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma.
In December 2010, GE Healthcare, a unit of General Electric Company (NYSE:GE), purchased Clarient, Inc. at an aggregate cash purchase price of approximately $570 million.
Location: Aliso Viejo, CA
2010 Revenues: ~$110M